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A QSAR analysis has been performed on a compound series of 1-11 
quinoacridinium derivatives as internal test compounds, and compounds of 
12-15 quinoacridinium derivatives as external test compounds. The 
electronic descriptors used in this study were atomic net charge (q), dipole 
moment (μ), ELUMO, EHOMO, polarizability (α), and Log P. They were calculated 
through HyperChem for Windows 8.0 software using semi-empirical PM3 
method. The antitumor activity (IC50) of quinoacridinium derivative 
compounds was obtained from literature. Furthermore, the model of QSAR 
equation was analyzed through RML method which produced the best QSAR 
equation model: Log IC50 = -13.010+15.338(qC3) - 4.31(qC4) - 155.308(qC9) 
+ 33.626(qC11) + 26.626(qC12) + 24.631(qC14) - 0.228(μ) - 0.621(ELUMO) - 
0.066(α) + 0.233(Log P). The model of QSAR equation has a correlation 
coefficient n =11, (r) = 1.00, (r2) =1.00, SE =0, and PRESS = 0.003. Among 28 
compounds of quinoacridinium derivative which were designed, only 15 
compounds, namely 16, 19-20, 22-28, 30-32, 39, and 40 compounds, have 
been recommended to be synthesized in the laboratory.  
Key words: quinoacridinium derivatives, QSAR analysis, anti-tumor, PM3 
method, MLR analysis 
 
 
INTRODUCTION  
Tumors and cancers still become dangerous 
health problem in the world because of their high 
morbidity and mortality. In 2012, there were 14.1 
million new cancer cases, with 8.2 million cancer 
deaths (Torre et al., 2015). In 2000, productivity 
costs which was lost due to cancer deaths were 
115.8 billion US dollars, and by 2020, these costs 
are predicted to reach 147.8 billion US dollars 
(Bradley et al., 2008). The main problems in a 
cancer therapy are low selectivity and high toxicity. 
Therefore, it is necessary to develop antitumor 
drugs with high selectivity as well as low toxicity, 
so that the therapy will be more effective. One of 
the antitumor compounds that has been widely 
studied and continuously developed by previous 
researchers is the derivatives of acridinium 
compounds.  
A recent study on acridinium derivatives 
was conducted in 2008 (Cheng et al., 2008). It was 
a synthesis on a series of salt-derivative compound 
with 8,13-dimethylquino[4,3,2-kl]acridinium as an 
antitumor. Derivatives of the acridinium 
compounds used as an antitumor have been 
studied (Cooksonet et al., 2005). Research on the 
derivatives of acridine compounds has been done 
by various researchers since 1984. They isolated 
acridine compounds from plant species, 
Lactariusnecator (Agaricales) (Fugmann et al., 
1984). Furthermore, after 13 years later, the ring of 
acridine compounds was successfully synthesized 
and antitumor activity was tested (Hagan et al., 
1997). After that in 1998, several researchers 
conducted a study to convert 9-azidoacridine to 
7H-pyrido [4,3,2-kl]acridine compound and 
succeeded in changing the pyridine ring to 7H-
pyrido[4,3,2-kl]acridine compound to increase the 
antitumor derivative activity of acridine 
compounds (Hagan et al., 1998;  Julino & Stevens, 
1998). In 2000, the ring of acridine compound was 
developed into tetra-, penta-, and hexacyclic rings in 
a heteroaromatic system through a cyclical process 
of 9-anilinoacridineto enhance antitumor activity 
of derivatives of acridine compounds which were 
synthesized in the previous years (Stanslas et al., 
2000;  Ellis et al., 2001). 
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Research on the derivatives of acridine 
compounds continues being developed by 
researchers. Some of them are the synthesis                       
of acridine polycyclic compounds, i.e. 8,13-diethyl-
6-methylquino[4,3,2-kl]acridinium iodide and 
3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-
kl]acridinium methosulfate (Missailidis et al., 2002; 
Leonetti, 2004). The synthesis of the acrylic 
polycyclic derivative was intended to increase the 
antitumor activity and the solubility of the 
compound (Missailidis et al., 2002; Leonetti, 2004). 
Efforts to obtain a more active antitumor through 
the derivatives of acridine compounds were 
continued by researchers through the synthesis of 
more polar and complex compounds using the 
alkylation method of polycyclic acridine 
compounds (Cookson et al., 2005). The 
development of antitumor compounds from 
polycyclic acridine has been carried out (Cheng et 
al., 2008). It is a salt compound of 8,13-
dimethylquino[4,3,2-kl]acridinium and has an 
antitumor activity (IC50) around 0.21 to 2.00 μM. 
The salt compound which has the highest activity is 
derivatives of 8,13-dimethylquino[4,3,2-
kl]acridinium which is bound up both with anionic 
iodine and an ester functional group on C2 atom of 
such cyclic compound ring. Antitumor activity of 
salt derivatives 8,13-dimethylquino[4,3,2-
kl]acridinium compound is still low when it is 
compared with antitumor compounds that have 
been circulating in the market (Cheng et al., 2008). 
Based on the results of the research  above, the 
efforts to develop antitumor compounds from 
other compounds have also been developed 
recently, such as o-isoselenazolon, and gallium-
pyridine complexes known as metal-based drugs 
with a very high anticancer activity (Schmitt & Dou, 
2013; Florea & Büsselberg, 2011; Luo et al., 2012). 
However, the development of an anticancer 
compound from heavy metals causes many 
metabolic risks to the human body. Other studies 
on anticancer and antitumor have also been done 
by many researchers (Miladiyah et al., 2016; Hosny 
et al., 2012; Alam et al., 2016; Reddy et al., 2012; 
Bladt et al., 2013; Heliawati et al., 2015; Noolvi and 
Patel, 2013; Deep et al., 2016; Shelton et al., 2016; 
Tripodi et al., 2012; Su et al., 2011). They 
consecutively isolated and modified the chemical 
structures on the following compounds: (1) 
derivatives of benzoylphenylurea; (2) derivatives 
of N-benzoyl cephalexin; (3) derivatives of benzoyl 
paracetamol mercaptotriazoles; (4) derivatives of 
coumarin and quinolinyl; (5) sesqui-
terpenecoumarin; (6) derivatives of tri-terpenoide 
saponin; (7) extracts of Acalyphaindica leaf; (8) 
derivatives of polyketide; (9) extracts of 
Scaevolaspinescens; (10) extracts from the 
Coryphautan Lamk; (11) derivatives of polyketide; 
(12) derivatives of 2,3,7-trisubstituted quinazoline; 
(13) derivatives of 2-azetidinone; (14) derivatives 
of glutathione; (15) derivatives of nucleoside and 
nucleotide; (16) derivatives of 1,4-diaryl-2-
azetidinones; and (17) xanthone derivative 
compounds (Miladiyah et al., 2016; Hosny et al., 
2012; Alam et al., 2016; Reddy at al., 2012; Bladt et 
al., 2013; Heliawati et al., 2015; Noolvi & Patel, 
2013; Deep et al., 2016; Shelton et al., 2016; Tripodi 
et al., 2012; Su et al., 2011). The antitumor activities 
of all compounds afore mentioned before are still 
low when they are compared with antitumor 
compounds that have been circulating in the 
market. All compounds which were isolated and 
modified generally have a functional group of 
primary amine (-NH2). Based on the results of the 
research above, to design the structure of 
antitumor or anticancer molecules, it is necessary 
to make a model of anticancer molecules whose 
structures are cyclic compounds and have 
functional groups of amine (-NH2). In this study it 
was attempted to synthesize quinoacridinium 
derivative compounds that have an amine 
functional group, so that they are antitumor 
compounds that meet this criterion. 
Based on the explanation above, the effort to 
find an antitumor compound from the 8,13-
dimethylquino[4,3,2-kl]acridinium which has a 
functional group -NH2 is still very potential to be a 
candidate for antitumor drugs which are expected 
to have activity high and friendly to the body. 
Efforts to develop an antitumor drug from 8,13-
dimethylquino[4,3,2-kl]acridinium derivatives 
need to be done through a computational chemistry 
approach with a Quantitative Structure-Activity 
Relationship (QSAR) analysis to obtain more           
active and body-friendly compounds. The QSAR 
analysis is one of the latest methods in the            
phases of developing new drugs. The results of 
QSAR analysis are generally used as a guide to 
design new drugs theoretically. In this study,                  
the results of QSAR analysis are used as guidance  
in designing compounds of 8,13-
dimethylquino[4,3,2-kl]acridinium derivatives that 
are potentially to be antitumor and have never 
been previously synthesized. The QSAR analysis 
approach as an effort to design drug compounds is 
very important because it minimizes the use of 
chemicals and energy. It also saves time because it 
can avoid trial and error experiments in laboratory.  
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However, it can still provide a relatively high level 
of confidence (Hadanu and Syamsudin, 2013). The 
QSAR analysis aims to find an empirically 
consistent relationship between the molecular 
properties and the biological activity of a series of 
homologous structural compounds of the drug. The 
QSAR study began to grow rapidly after1960. It was 
pioneered by Corwin Hansch who connected 
chemical structures with drug biology activities 
through common chemical-physical properties 
such as fat solubility, ionization degree, and 
molecular size. Later on in the last few decades, it 
was developed more intensively into a quantitative 
relationship between biological activity and 
various chemical-physical parameters such as                 
net atomic charge, ELUMO-EHOMO, solubility in                        
fat (polarisabilities), solubility in water and              
alcohol (Log P), molecular size, hydrophobic 
parameters, electronics and sterics in a series                   
of    molecules    (Hadanu   and   Syamsudin,   2013).  
The relationship between physical as well as 
chemical properties and biological activity is 
proposed by (Ferguson et al., 1997) with an 
equation that can be used to relate some activity 
data with the following parameters: 
 
Log BR = f(P1, P2, P3)……………………………………….(1)  
                         
BR (Biological Response) is a biological 
activity or biological response as an algebraic 
function of 3 parameters P1, P2, and P3 which is the 
nature of the structure under investigation. The 
development of QSAR analysis in the next period 
uses the net charge of the atom as an estimator and 
expressed by: 
 
Log BR = CqP
i
ii   ………………………………..(2) 
Pi is the fitting parameter for ith atom, and qi 
is the net charge of the atoms and other parameters 
for the ith atom and C is constant. In the 
development of subsequent research, QSAR study 
is very helpful in the search for new drugs with 
greater activity, higher selectivity, toxicity or minor 
side effects, and greater comfort. In addition, using 
the QSAR equation model can save more money 
because to get a new drug with high activity, the 
experimental factor can be minimized as much as 
possible (Hadanu et al., 2015). 
Some attempts at cancer treatment have 
been performed in various ways such as surgery, 
radiation, anticancer drug treatment or 
chemotherapy. However, these efforts have not 
achieved satisfying results; even the effects of 
surgical failure can cause cancer to spread to other  
parts of the body with severe conditions (Nugraha 
et al., 2018). This encourages the development of 
new medicine from 8,13-dimethylquino[4,3,2-
kl]acridinium compound which is more active, 
friendly to the body, and expectedly to have a good 
therapeutic effect. 
 
MATERIAL AND METHODS 
The materials used in this study were 
quinoacridinium derivative compounds that have 
been synthesized by Cheng et al., (2008). Inhibition 
Concentration (IC50) was used as the dependent 
variable (Table I and II) (Cheng et al., 2008). 
 
Instrumentation 
In this study, the tools used for QSAR test 
were computer hardware devices namely a Sony 
Vaio Laptop with Intel® Dual Core Processor 2.20 
GHz; 1 GHz RAM, and HDD 250 GB. Meanwhile, the 
software used in this study is HyperChem 8.0 for 
Windows for optimization purposes of 3D structure 
and geometry optimization of the chemical 
structure of tested compounds  (compounds 1-11), 
external test compounds (compounds 12-15) and 
the structure of quinoacridinium derivative 
compounds (compound 16-43). For statistical 
analysis to obtain the QSAR equation, SPSS 19.0 for 
Windows was used.  
 
Calculating the descriptors 
Internal fitting compounds (Table I), 
external fitting compounds (Table II), and 
modeling compounds (Table V) were constructed 
respectively in three-dimensional (3D) structures 
with the HyperChem 8.0 for Windows program-
ming package. Furthermore, the geometric 
structures of all fitting compounds and model 
compounds were optimized to obtain more stable 
structural conformation using the semi-empirical 
PM3 method. This method is chosen because              
semi-empirical methods can be performed 
descriptor calculations   quickly    and   accurately. 
The semi-empirical method is faster than                            
the ab-initio method although it is less accurate  
and the semi-empirical method is more accurate  
than the AM1 method even though it is slower                
than the AM1 method. In addition, semi-empirical 
methods are methods that use experimental                   
and theoretical data sets. When viewed with                   
the molecular structure used, semi-empirical 
methods are suitable, because the quinoacridinium 
molecule have a medium molecular weight                     
and    functional   groups    -NH2,   -NHR,    and   -NR2.  
  
Antitumor Agents using a QSAR analysis 
 
170   Volume 30 Issue 3 (2019) 
The structural optimization was performed by 
using Polak-Ribiere algorithm optimization 
method with RMS value = 0.001 kcal/(Å.mol), 
which was recorded through the single point menu. 
Via the data fromthe single point menu, the 
electronic parameters such as the net atomic 
charge, the dipole moment (μ), the polarization (α), 
and the Log P were obtained. Meanwhile, the ELUMO 
and the EHOMO were obtained from compute and 
orbital menus which were presented (Table III and 
IV). The selection of descriptor type was adjusted 
to the type of descriptor used by Motta et al., (2006) 
in conducting QSAR analysis. The structure of the 
quinoacridinium derivative compounds as the 
study material was calculated by involving an ion 
counter of salt. 
 
QSAR equation analysis by using a linear 
regression method 
 The dependent variable in this study was 
the antitumor activity with IC50value based on 
experiment (Table I), while the independent 
Table I. Chemical structure and activity data of antitumor compounds of quinoacridinium derivatives 
obtained from Cheng et al., (2008) 
 
N
N
R
R
R
R R
R
R
R
R
R
R
R
R
1
2
3
4
5
6
789
10
11
12
13
14
15
1617
1819
20
X
1
2
3
4
5
6
789
10
11
13
12
21
 
Compounds R2 R3 R6 R8 R10 R11 R13 X- 
IC50  
(µM) 
Log 
IC50 
1 H H CH3 C2H5 H H C2H5 I- 2.00 0.30 
2 H CH3 CH3 CH3 H CH3 CH3 H3COSO3- 0.25 -0.60 
3 H H CH3 CH3 H H CH3 H3COSO3- 0.74 -0.13 
4 H H H CH3 H H CH3 I- 1.55 0.19 
5 NHCOCH3 H H CH3 H H CH3 I- 0.38 -0.42 
6 NHCOCF3 H H CH3 H H CH3 I- 0.31 -0.51 
7 NHCO(CH2)4CO2CH3 H H CH3 H H CH3 I- 0.21 -0.68 
8 N(CH3)SO2C6H4-p-F H H CH3 H H CH3 I- 0.73 -0.14 
9 H NHCOCH3 H CH3 H H CH3 I- 0.41 -0.39 
10 H Cl OCH3 CH3 H H CH3 I- 0.28 -0.55 
11 H CH=CHCON(CH2CH2)2O H CH3 H H CH3 I- 0.37 -0.43 
 
Table II. The chemical structure of external standard compounds of quinoacridinium derivatives from 
Cheng et al., (2008). 
 
N
N
R
R
R
R R
R
R
R
R
R
R
R
R
1
2
3
4
5
6
789
10
11
12
13
14
15
1617
1819
20
X
1
2
3
4
5
6
789
10
11
13
12
21
 
Compounds R2 R3 R6 R8 R10 R11 R13 X- 
IC50 
(µM) 
Log IC50 
12 H F CH3 CH3 H F CH3 H3COSO3- 0.33 -0.48 
13 NH2 H H CH3 H H CH3 I- 1.86 0.27 
14 NHCOC(CH3)3 H H CH3 H H CH3 I- 0.23 -0.64 
15 H Cl H CH3 H H CH3 I- 0.26 -0.59 
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variables used were net atomic charges, dipole 
moment (μ), ELUMO, EHOMO, polarizability (α), and 
Log P (Tables III and IV). All variables were 
analyzed using enter method through MLR to find 
out which sequence of independent variables 
influenced the antitumor activity value of 
quinoacridinium derivative compounds. The result 
generated QSAR equations as well as statistical 
parameters such as r, r2, SE, and PRESS values. In 
addition to the statistical parameters, the 
calculation result also obtained the constant value 
and the coefficient value of each independent 
variable involved in the equation result. The 
obtained coefficient value was used to calculate the 
theoretical antitumor activity (IC50 theoretical 
value) toward quinoacridinium derivative 
compounds. Furthermore, after finding out the 
square difference betweenthe IC50 experimental 
value andthe IC50 theoretical value, the PRESS value 
can be calculated to know the quality and 
prediction ability of the best equation of the QSAR 
model. 
 
Design of new antitumor molecules 
The design of new antitumor drug molecules 
in this study was aimed to discover novel 
Table III. Log IC50 experiments and Log IC50 calculated of external test compounds 
 
Compounds Log IC50 experiments Log IC50 calculated 
12 -0.48 -0.359 
13 0.27 0.166 
14 -0.64 -0.602 
15 -0.59 -0.589 
 
Table IV. Descriptors/independent variables used for QSAR analysis of antitumor compounds of 
quinoacridinium derivatives calculated by the semi-empirical PM3 method 
 
Comp. 
Number 
Atomic net charges (Coulomb) 
qC1 qC2 qC3 qC4 qC5 qC6 qC7 qN8 qC9 qC10 qC11 qC12 qN13 
1 -0.075 -0.060 -0.077 -0.083 -0.160 0.033 -0.193 0.200 -0.179 -0.015 -0.112 -0.039 0.200 
2 -0.056 -0.072 -0.038 -0.095 -0.153 0.023 -0.187 0.188 -0.165 -0.034 -0.062 -0.054 0.523 
3 -0.069 -0.067 -0.073 -0.090 -0.155 0.024 -0.189 0.188 -0.182 -0.025 -0.114 -0.073 0.491 
4 -0.019 -0.077 -0.064 -0.098 -0.145 -0.015 -0.179 0.170 -0.170 -0.030 -0.124 -0.046 0.573 
5 -0.139 -0.014 -0.126 -0.054 -0.153 0.001 -0.187 0.194 -0.175 -0.017 -0.115 -0.042 0.458 
6 -0.052 -0.058 -0.104 -0.066 -0.146 -0.010 -0.179 0.175 -0.170 -0.026 -0.124 -0.044 0.558 
7 -0.152 -0.015 -0.131 -0.050 -0.144 -0.017 -0.178 0.187 -0.173 -0.031 -0.115 -0.057 0.420 
8 -0.207 0.087 -0.138 -0.042 -0.156 0.002 -0.187 0.189 -0.176 -0.017 -0.115 -0.029 0.453 
9 -0.065 -0.095 -0.043 -0.131 -0.138 -0.022 -0.171 0.187 -0.170 -0.033 -0.111 -0.060 0.432 
10 -0.003 -0.081 -0.099 -0.101 -0.191 0.178 -0.264 0.171 -0.168 -0.030 -0.122 -0.045 0.562 
11 -0.086 -0.074 -0.038 -0.064 -0.139 -0.020 -0.174 0.189 -0.172 -0.032 -0.111 -0.060 0.416 
Comp. 
Number 
Atomic net charges (Coulomb) μ 
(Debye) 
ELUMO  
(ev) 
EHOMO 
(ev) 
α 
(Å3) 
Log P 
qC14 qC15 qC16 qC17 qC18 qC19 qC20 qC21 
1 -0.126 -0.052 0.067 0.073 -0.145 -0.145 -0.019  0.012 20.946 -2.563 -4.236 46.27 2.12 
2 -0.161 -0.025 0.052 0.017 -0.127 -0.120 -0.043  0.003 18.287 -2.291 -8.730 45.49 0.94 
3 -0.154 -0.040 0.057 0.037 -0.136 -0.141 -0.031  0.005 16.840 -2.252 -8.784 41.82 0.63 
4 -0.124 -0.033 0.056 0.000 -0.113 -0.119 -0.025 -0.010 13.352 -2.078 -5.712 40.77 1.28 
5 -0.115 -0.079 0.070 0.049 -0.135 -0.139 -0.022 -0.003 15.507 -2.541 -4.590 45.88 -0.61 
6 -0.098 -0.049 0.060 0.018 -0.119 -0.124 -0.024 -0.008 14.899 -2.311 -5.323 45.60 0.50 
7 -0.094 -0.065 0.048 -0.005 -0.100 -0.112 -0.029 -0.015 12.513 -2.478 -5.327 55.77 0.00 
8 -0.083 -0.084 0.077 0.074 -0.134 -0.139 -0.022   0.001 15.889 -2.456 -4.310 54.66 -0.56 
9 -0.149 -0.008 0.028 -0.014 -0.091 -0.107 -0.031 -0.017 14.072 -2.604 -5.459 45.88 -0.61 
10 -0.121 -0.028 0.087 0.016 -0.150 -0.117 -0.028 0.031 15.096 -2.151 -5.098 45.17 0.06 
11 -0.127 -0.033 0.035 -0.007 -0.094 -0.108 -0.030 -0.017 15.213 -2.558 -5.367 54.72 0.36 
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compounds of quinoacridinium derivatives which 
have higher antitumor activity than previously 
synthesized compounds. The molecular design was 
performed by varying the type and position of 
substituent or functional group positions in the 
main framework structure of quinoacridinium 
derivative compounds. The substituent position 
was focused on the active center area by 
considering the feasibility of synthesis in the 
laboratory.  The  substituent  or  functional group is  
the dominantly responsible atoms of the antitumor 
activity of the quinoacridinium derivatives. After 
finding out the quinoacridinium molecular 
sequence series, the next step is calculating the 
descriptor of the new compound of modeling 
design (Table VI and VII) by using the semi-
empirical method of PM3 using HyperChem 8.0 for 
Windows. Based on the best QSAR equations, we 
can calculate the theoretical antitumor activity of 
the design compounds (Table VI and VII). 
 
Table VI. The New designed quinoacridinium derivatives as antitumor compounds 
 
N
N
R
R
R
R
R
R
R
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1617
1819
20
X
2
3
6
8
10
11
13
21
 
Compounds 
Substituents 
R2 R3 R6 R8 R10 
16 H Cl CH3 CH3 H 
17 NHCH3 H H CH3 H 
18 N(CH3)2 H H CH3 H 
19 NHCOC4H9 H H CH3 H 
20 NHCOC11H23 H H CH3 H 
21 NHCO2C2H5 H H CH3 H 
22 NHCOPh H H CH3 H 
23 H H OCH3 CH3 Cl 
24 H H OCH3 CH3 CH=CHCON(CH2CH2)2O 
25 H H OCH3 CH3 CH=CHCO2CH3 
26 H H (CH2)3OCOCH3 CH3 (CH2)3OCOCH3 
27 H Cl CH=CHCON(CH2CH2)2O CH3 H 
28 H CH=CHCON(CH2CH2)2O OCH3 CH3 H 
29 H CH=CHCON(CH2CH2)2O (CH2)3OCOCH3 CH3 H 
30 H (CH2)3OCOCH3 (CH2)3OCOCH3 CH3 H 
31 H Cl CH3 CH3 H 
32 H Cl CH3 C2H5 H 
33 N(C2H5)2 H H CH3 H 
34 N(C2H5)2 H H C2H5 H 
35 NHCOC3H7 H H C3H7 H 
36 NHCOC2H5 H H C2H5 H 
37 NHCOC11H23 H H C2H5 H 
38 NHCOPh H H C2H5 H 
39 H H (CH2)3OCOCH3 C2H5 (CH2)3OCOCH3 
40 H Cl CH=CHCON(CH2CH2)2O C2H5 H 
41 H CH=CHCON(CH2CH2)2O OC2H5 C2H5 H 
42 H CH=CHCON(CH2CH2)2O (CH2)3OCOCH3 C2H5 H 
43 H (CH2)3OCOC2H5 (CH2)3OCO C2H5 C2H5 H 
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RESULT AND DISCUSSION 
The stages of quantitative relationship 
analysis of structures carried out in this study were 
(a) determining series of quinoacridinium 
compounds which had IC50 values based on 
experiment in the laboratory Cheng et al., (2008); 
(b) optimizing the basic structural framework of 
the most stable quinoacridinium derivative as the 
initial compound in the process of optimizing the 
test compound for further analysis; (c) determining 
descriptor (independent variable); (d) calculating 
descriptor through optimization structure of tested 
compounds (optimization of derivative structure of 
tested compound) (Table I and II); (e) performing 
correlation analysis between variables through 
bivariate correlation method; (f) performing 
multilinear regression analysis to obtain the model 
of QSAR equation; (g) determining the best QSAR 
equation  model  (Hadanu   and   Syamsudin,  2013;  
 
Hadanu et al., 2015) and (h) designing a new 
compound of quinoacridinium derivatives based 
on the best QSAR equation model. 
Table VII. Predicted Log IC50 calculated using the best QSAR model 
 
N
N
R
R
R
R
R
R
R
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1617
1819
20
X
2
3
6
8
10
11
13
21
 
Compounds 
Substituents 
Predicted Log IC50 Predicted IC50 
R11 R13 X- 
16 Cl CH3 H3COSO3- -5.692 0.000002 
17 H CH3 I- -0.111 0.775149 
18 H CH3 I- 0.080 1.201752 
19 H CH3 I- -0.901 0.125555 
20 H CH3 I- -0.760 0.173970 
21 H CH3 I- -0.315 0.484069 
22 H CH3 I- -0.894 0.127722 
23 H CH3 I- -1.036 0.091970 
24 H CH3 I- -3.928 0.000118 
25 H CH3 I- -3.400 0.000398 
26 H CH3 I- -1.743 0.018086 
27 H CH3 I- -1.254 0.055728 
28 H CH3 I- -0.910 0.122898 
29 H CH3 I- -0.040 0.912860 
30 H CH3 I- -1.460 0.034668 
31 Cl C2H5 H5C2OSO3- -5.414 0.000004 
32 Cl C2H5 H5C2OSO3- -1.745 0.017990 
33 H C2H5 I- 0.522 3.327068 
34 H C2H5 I- 0.955 9.013149 
35 H C3H7 I- -0.329 0.468765 
36 H C2H5 I- 0.847 7.031945 
37 H C2H5 I- 0.001 1.001424 
38 H C2H5 I- -0.113 0.770079 
39 H C2H5 I- -1.391 0.040617 
 40 H C2H5 I- -0.805 0.156537 
41 H C2H5 I- 2.139 137.657528 
42 H C2H5 I- -0.699 0.200199 
43 H C2H5 I- 0.093 1.237455 
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The quinoacridinium derivative compounds 
as the materials in this study has the following 
requirements: (1) the basic framework structure of 
the homologous compound should be possessed by 
all fittings compounds, external test compounds, 
and the modeled compound; (2) the fitting 
compound; and (3) the external test compound 
should have IC50 value which is experimented in a 
laboratory. The optimization of the structures of all 
fitting compounds, external test compounds, and 
the modeled compounds was carried out by the 
same method to obtain the most stable structural 
compound with the lowest energy profile. When all 
of compound structures are at the lowest profile 
energy, they are in the most stable condition. In 
that condition, the descriptor (independent 
variable) required in the next stage of QSAR 
analysis can be obtained. 
 
By bivariate correlation analysis, it is                 
clear that the variables of atomic net charge,                
dipole moment (μ), EHOMO-ELUMO, polarisabilities             
(α),   and   Log   P   showed  a  very close correlation.  
This is indicated by the absolute value of the 
correlation which is closer to 1 or -1. The evidence 
of such close correlation can be seen in some of the 
relationships between descriptors that have a high 
correlation, for example: the correlation between 
variables QC1-QC2 (-0.893), qC6-qC5 (-0.898), 
QC2-qC4 (0.774), qC7-qC5 (0.994), qC5-QC10 (-
0.754), qC6-qC7 (-0.920), QC1-qC15 (0.823), QC2-
qC15 (-0.865), QC3-qC14 (-0.825), QC3-qC15 
(0.831), qC4-qC14 (0.773), qC4-qC15 (-0.897), 
qN8-qN13 (-0.837), qC5-qC16 (-0.820), qC5-qC17 
(-0.913), qC5-qC18 (0.961), qC5-qC19 (0.910), 
qC6-qC17 (0.724), qC6-qC18 (-0.863), qC6-qC19               
(-0.766), qC7-qC16 (-0.791), qC7-qC17 (-0.890), 
 
 
 
Figure 1. Correlation between Log IC50 calculated from the internal test compound and Log IC50 experiment 
 
 
 
 
 
Figure 2. Correlation between Log IC50 of the external test compound and Log IC50 experiment 
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qC7-qC18 (0.963), qC7-qC19 (0.906), QC1-α                     
(-0.759), qC5-qC21 (-0.961), qC5-μ (-0.764), qC6-
qC21 (0.968), qC6-μ (0.903), qC7- qC21 (-0.967), 
qC7-μ (-0.778), and qN8-ELUMO (-0.768). The 
negative value of such correlation does not indicate 
whether the substituent influence on antitumor 
activity is strong or not, but it only shows                   
the direction of the effect. A negative value 
indicates correlation of a negative association, 
which means that the effect of one variable is 
inversely proportional to other variables. The 
relationship between the smallest independent 
variables is the qN8-qN13 (0.001) variable, which 
indicates that the qN8 variable and qN13 have a 
weaker relationship than other independent 
variables. Meanwhile, the relationship between the 
largest independent variables is variable qC7-qC5 
(0.994) which shows that between variables qC7 
and qC5, there is stronger relationship than other 
independent variables. Based on the bivariate 
correlation analysis, it can be concluded that 
between the independent variable and dependent 
variable, there is a significant relationship. Thus, 
MLR analysis can be performed on a group of the 
data in this research. 
The MLR analysis on a group of independent 
variables as descriptor and dependent variable or 
antitumor activity (Log IC50) produced a model of 
QSAR equation which is the best model of QSAR 
equation. The best QSAR model built using MLR 
method is represented by the following equation: 
 
Log IC50 = -13.010 + 15.338(qC3) - 4.31(qC4) - 
155.308(qC9) + 33.626(qC11) + 26.626(qC12) + 
24.631(qC14) - 0.228(μ) - 0.621(ELUMO)–0.066(α) + 
0.233(Log P) ……………………………………………….....(3) 
 
The statistical significance of the best QSAR            
models has coefficient correlation n=11, (r)=1.00, 
(r2)=1.00, SE=0, and PRESS = 0.003. 
 
To test the accuracy of the model of the 
obtained QSAR equation, it is necessary to calculate 
the IC50 prediction value of the internal test 
compound (Table I). The proof of the accuracy of 
the model of QSAR equation can be seen on the 
graph of Log IC50 value of prediction with an IC50 
value of the experimental internal test (compounds 
1-11) (Figure 1). The graph shows the relationship 
between the Log IC50 prediction value of the 
internal test compound and Log IC50 experiment   
with   obtained    value  r2 = 0.993. The value of r2 is 
close to 1, which indicates that the internal test 
model of QSAR equation has a very high level of 
trust. 
To test the validity of the model of QSAR 
equation, a validity test has been performed by 
using external test compounds (compounds 12-
15). The external test compound is a 
quinoacridinium compound derivative which has 
been known as IC50 experimental value, but it is not 
included in the calculation process in determining 
QSAR equation model. This is intended to validate 
the QSAR model more accurately since it is 
validated with internal test compounds and 
external test compounds. The IC50 value of external 
compound test (Table III). 
The graphic of correlation between Log IC50 
calculated and Log IC50 experiments value has 
r2=0.9701 (Figure 2). It shows that the QSAR 
equation model obtained in this research is the best 
QSAR equation for determining the IC50 value of 
compound derivative quinoacridinium. The high 
value of r2 (close to 1) displayed in the correlation 
graph between Log IC50 calculated from the 
external test compound and the Log IC50 value of 
the experiments reinforces the QSAR model as an 
equation with high validity. 
Based on the value of r2 = 0.9701 obtained 
from the correlation between Log IC50 of calculated 
from external test compound and Log IC50 
experiment, it proves that the relationship between 
calculated IC50 value of external test compound and 
Log IC50 value of experiment is very strong. Thus, it 
can be concluded that the model of QSAR equation 
obtained by using MLR analysis is very significant 
to determine the value of Log IC50 compounds 
models of quinoacridinium derivatives. 
 
Design of new antitumor quinoacridinium 
derivative compounds 
The molecular design of the 
quinoacridinium derivative remains concerned 
with the active side of the homologous and atomic 
frameworks or the functional groups bound to the 
basic framework structure of the compound. The 
differences of atoms or functional groups bound to 
the basic frameworks of homologous compounds of 
quinoacridinium derivatives may cause different 
charges of atoms and differences in physical and 
chemical properties. In addition, it also causes 
differences in antitumor activity of such 
compounds (Hadanu et al., 2015). The obvious that 
compounds which have different structures can 
produce different antitumor activity (Table I-V). 
Based on this fact, it can be concluded that different 
structures have electronic properties and 
molecular properties (different net charge of atoms 
and other descriptors). Compounds that have 
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different electronic and molecular properties 
absolutely produce different antitumor activity. 
Based on the above explanation and QSAR 
model equations (3), atomic charge values of qC3, 
qC4, qC9, qC11, qC12, qC14, μ, ELUMO, α, and Log P 
for respective designed compounds are variables 
influencing the value of antitumor activity (IC50) of 
quinoacridinium derivatives. In designing the 
molecule, it is necessary to consider the attachment 
of the atom or functional groups to the main 
framework of quinoacridinium derivatives which 
can cause the change of atomic charge value of qC3, 
qC4, qC9, qC11, qC12, qC14, μ, ELUMO, α, and Log P, 
so that it can cause different predictions of IC50 
value (Table V). The calculation of atomic charges 
and other descriptors obtained from each of the 
new compounds is incorporated into the QSAR 
model of equation (3) in order to obtain theoretical 
IC50 values of the novel compound derived from the 
modeling design. Compounds that have a small IC50 
value are antitumor compounds that have the 
highest antitumor activity. The smaller IC50 value of 
a quinoacridinium derivative compound is, the 
higher the chances of the compound as an 
antitumor drug is and it may be proposed for 
synthesis in the laboratory. 
The calculated IC50value of new molecules 
from the quinoacridinium derivatives design 
(Table VI and VII). Some compounds from 
quinoacridinium (Table VI and VII) derivative 
design are proposed for synthesis, in which they 
have an IC50 value smaller than IC50 of fifteen 
quinoacridinium derivatives (Tables I and II). Thus 
the quinoacridinium derivatives compounds 
derived from the recommended modeling design 
are: compounds 16 (IC50=0.000002μM), 19 
(IC50=0.125555μM), 20 (IC50=0.173970μM), 22 
(IC50=0.127722μM), 23 (IC50=0.091970μM) 24 
(IC50=0.000118μM), 25 (IC50=0.000398μM), 26 
(IC50=0.018086μM), 27 (IC50=0.055728μM) 28 
(IC50=0.122898μM), 30 (IC50=0.034668μM) 31 
(IC50=0.000004μM), 32 (IC50=0.017990μM), 39 
(IC50=0.040617  μM), and 40 (IC50=0.156537 μM). 
Theoretically, they can be proposed for synthesis in 
the laboratory. Certainly, in the synthesis process 
in the laboratory, it is prioritized to synthesize 
compounds that have smaller IC50 values and 
compounds that have the easy synthesis pathways 
in the laboratory, as well as the availability of 
chemicals (Hadanu and Syamsudin, 2013; Hadanu 
et al., 2015). The theoretical IC50 value of the 
quinoacridinium derivatives is less than the IC50 
value determined by the National Cancer Institute 
(NCI) for the compounds extracted from the 
natural material. According to the National Cancer 
Institute (NCI), an extract is considered to have an 
active anticancer activity if its IC50 value is <30 
μg/mL, moderate active anticancer activity if its 
IC50value is ≥ 30 μg/mL, IC50<100 μg/mL, and 
inactive anticancer activity if its IC50 value is >100 
μg/mL.2 
Based on the structure model of the QSAR 
analysis recommended for synthesis in the 
laboratory, it can be concluded that the 
quinoacridinium derivatives which have high and 
potential antitumor activities are quinoacridinium 
derivatives which have functional groups as 
follows: -Cl is bound to C3 and C11 atoms; the -CH3 
function group is bound to C6, C8, and C13 atoms, 
anion H3COSO3-;-OCH3 functional group is bound to 
C6 atom, anion iodide (I-); functional group of -
CH=CHCON(CH2CH2)2O is bound to C6 and C10 
atoms; the functional group of-(CH2)3OCOCH3 is 
bound to C3, C6, and C10;–C2H5 functional group is 
Table V. Descriptors/independent of external standard for QSAR analysis of antitumor compounds of 
quinoacridinium derivatives calculated by the semi-empirical PM3 method 
 
Comp. 
Number 
Atomic net charges (Coulomb) 
qC1 qC2 qC3 qC4 qC5 qC6 qC7 qN8 qC9 qC10 qC11 qC12 qN13 
12 -0.032 -0.091 0.103 -0.136 -0.147 0.024 -0.182 0.188 -0.152 -0.062 0.059 -0.113 0.527 
13 -0.083 -0.043 -0.112 -0.060 -0.152 -0.011 -0.185 0.171 -0.170 -0.030 -0.125 -0.045 0.565 
14 -0.154 -0.011 -0.132 -0.050 -0.145 -0.017 -0.179 0.187 -0.173 -0.032 -0.115 -0.057 0.418 
15 -0.002 -0.083 -0.096 -0.105 -0.142 -0.014 -0.176 0.172 -0.169 -0.029 -0.123 -0.045 0.577 
Comp. 
Number 
Atomic net charges (Coulomb) μ 
(Debye) 
ELUMO  
(ev) 
EHOMO 
(ev) 
α 
(Å3) 
Log P 
qC14 qC15 qC16 qC17 qC18 qC19 qC20 qC21 
12 -0.184 -0.006 0.047 0.013 -0.126 -0.104 -0.045 0.001 17.825 -2.485 -8.947 41.64 -0.57 
13 -0.083 -0.076 0.072 0.011 -0.122 -0.121 -0.024 -0.007 12.141 -2.084 -5.097 42.12 -0.44 
14 -0.093 -0.067 0.049 -0.005 -0.100 -0.111 -0.029 -0.015 12.211 -2.446 -5.288 51.38 1.24 
15 -0.128 -0.020 0.053 0.005 -0.112 -0.120 -0.025 -0.010 13.966 -2.229 -5.155 42.70 1.05 
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bound to C13 atom, anion H5C2OSO3-. Those all are 
bound to the main framework of quinoacridinium 
compounds. Nearly all compounds modeled 
according to Lipinski's Rule are quinoacridinium 
derivative compounds having fewer than 5 
hydrogen bond donors (nitrogen or oxygen atoms 
with one or more hydrogen atoms), less than 10 
hydrogen bond acceptors (nitrogen or oxygen 
atoms), and having an octanol-water partition 
coefficient (Log P) is less than 5. 
 
CONCLUSION 
Based on the results and discussion, it can be 
concluded that the best model of QSAR equation 
which shows the relationship between antitumor 
activity and latent variables to 11 compounds of 
quinoacridinium derivatives is: Log IC50 = -13.010 
+ 15.338(qC3) - 4.31(qC4) - 155.308(qC9) + 
33.626(qC11) + 26.626(qC12) + 24.631(qC14) - 
0.228(μ) - 0.621(ELUMO) - 0.066(α) + 0.233(Log P); 
n = 11, (r) = 1.00, (r2) = 1.00, SE = 0, and PRESS = 
0.003. A good correlation was observed between 
the experimental and predicted values of the 
anticancer activity (R=0.993), which indicated the 
validity and quality of the QSAR model developed 
in this work. Therefore, we conclude that the 
descriptors studied (e.g., atomic charge values qC3, 
qC4, qC9, qC11, qC12, qC14, μ, ELUMO, α, and Log P), 
which influenced the structural features of the 
quino-acridinium, can be used in tandem with 
other topological descriptors for the development 
of predictive QSAR models. The design of 
quinoacridinium derivative compounds which 
have high theoretical antitumor activity and are 
recommended for synthesizing in the laboratory 
are 16 of 28 compounds. Such designed compounds 
are 16, 19, 20, 22 to 28, 30, 32, 39, and 40. 
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